Lixisenatide shows efficacy in type 2 diabetes management

04/5/2012 | Medscape (free registration)

A higher proportion of drug-naive type 2 diabetes patients achieved blood glucose levels lower than 7% with once-daily lixisenatide for 12 weeks compared with those who received placebo treatment, researchers reported in Diabetes Care. Lixisenatide-treated patients also had bigger drops in two-hour postprandial glucose levels than those in the placebo group, researchers noted.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD